The difference between "A" and "U" makes all the difference...

We're uniquely positioned at the top of current research in this field.

The lack of current treatment options for Frontotemporal Dementia with Parkinsonism and Alzheimer’s is glaring making our work unavoidably urgent for us

Effectively thwarting the onset and/or progression of these life threatening diseases through our growing knowledge of SMiRNA is our goal.

Tau (AD) pre-mRNA splicing

Frontotemporal Dementia with Parkinsonism (FTDP-17) and Alzheimer’s

Program

From Care

– to Cure

Reduced 4R/3R mRNA Ratio in hTau Mouse Model

Expansion has assembled key platform enabling technologies and tools to allow for the identification of specific and potent novel small molecule binders of RNA outside of the bacterial ribosome. We have demonstrated the ability to identify small molecules interacting with RNA (SMiRNA™), including mRNA and various non-coding RNAs, across multiple therapeutic areas.

Small Molecules that Selectively Target RNA

Small Molecules and the Blood Brain Barrier

The Science

Bioavailable Tau-BT

Oral Delivery